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Cardiovascular disease is a major cause of morbidity and mortality in COPD patients. Sys-
temic inflammation associated with COPD, is often hypothesised as a causal factor. p38
mitogen-activated protein kinases play a key role in the inflammatory pathogenesis of
COPD and atherosclerosis.
Objectives
This study sought to evaluate the effects of losmapimod, a p38 mitogen-activated protein
kinase (MAPK) inhibitor, on vascular inflammation and endothelial function in chronic
obstructive pulmonary disease (COPD) patients with systemic inflammation (defined by
plasma fibrinogen >28g/l).
Methods
This was a randomised, double-blind, placebo-controlled, Phase II trial that recruited COPD
patients with plasma fibrinogen >2.8g/l. Participants were randomly assigned by an online
program to losmapimod 75mg or placebo tablets twice daily for 16 weeks. Pre- and post-
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dose 18F-Fluorodeoxyglucose positron emission tomography co-registered with computed
tomography (FDG PET/CT) imaging of the aorta and carotid arteries was performed to
quantify arterial inflammation, defined by the tissue-to-blood ratio (TBR) from scan images.
Endothelial function was assessed by brachial artery flow-mediated dilatation (FMD).
Results
We screened 160 patients, of whom, 36 and 37 were randomised to losmapimod or placebo.
The treatment effect of losmapimod compared to placebo was not significant, at -005 for
TBR (95% CI: -017, 007), p = 042, and +040% for FMD (95% CI: -166, 247), p = 070.
The frequency of adverse events reported was similar in both treatment groups.
Conclusions
In this plasma fibrinogen-enriched study, losmapimod had no effect on arterial inflammation
and endothelial function at 16 weeks of treatment, although it was well tolerated with no sig-
nificant safety concerns. These findings do not support the concept that losmapimod is an
effective treatment for the adverse cardiovascular manifestations of COPD.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a complex condition, which is associated
with extra-pulmonary manifestations, such as systemic inflammation and cardiovascular dis-
ease, that increase patient morbidity and mortality [1]. Current pharmacological treatments
for COPD are generally limited to inhaled bronchodilators and corticosteroids, which do not
address extra-pulmonary features. Diversifying therapeutic options to focus on systemic mani-
festations, and by implication more accurate stratification of COPD patients for such treat-
ments, might improve clinical outcomes.
p38 mitogen-activated protein kinases (MAPK) are signalling molecules that regulate cellu-
lar responses to extra-cellular stresses [2]. They also regulate pro-inflammatory cytokines, and
have a key role in the initiation and development of inflammatory diseases, including COPD
and atherosclerosis [2] [3]. Therefore, pharmacological inhibition of the p38 MAPK pathway,
may represent a potential novel approach to treating the adverse cardiovascular manifestations
of COPD. To date, losmapimod (GW856553 Brentford UK), a selective p38α/β MAPK inhibi-
tor has been evaluated as an anti-inflammatory therapy in different patient populations includ-
ing COPD and cardiovascular disease. In COPD, losmapimod reduces acute phase circulating
proteins such as fibrinogen, and a reduction in hyperinflation have been described [4]. In car-
diovascular disease, losmapimod attenuated arterial inflammation in atherosclerosis [5],
improved endothelial function in hypercholesterolemic subjects [6], and showed a trend
towards improved left ventricular function following non-ST elevation myocardial infarction
[7].
Arterial inflammation, measured by positron emission tomography (PET) imaging, is a
promising vascular biomarker, which has been shown to improve prediction of cardiovascular
events beyond traditional risk factors, and also informed on the timing of such events [8]. Bra-
chial artery flow-mediated dilatation (FMD) is a measure of endothelial function which is asso-
ciated with cardiovascular outcomes, and has prognostic value in different clinical cohorts [9].
COPD patients have increased arterial inflammation compared to healthy controls, regardless
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of smoking history [10], and also demonstrate impaired endothelial function [11]. Addition-
ally, systemic inflammation is hypothesised to be a causal factor in the increased cardiovascular
risk observed in COPD patients [1]. Plasma fibrinogen, a stable biomarker of systemic inflam-
mation in COPD, is positively associated with cardiovascular risk in the general population,
and is implicated in the development of vascular dysfunction and atherosclerosis [12]. It has
also recently been qualified by the Food and Drug Administration (FDA) as a drug develop-
ment tool for predicting the risk for COPD exacerbations, and mortality in COPD [13].
The EVOLUTION (Evaluation of Losmapimod in Chronic Obstructive Pulmonary Disease
patients with systemic inflammation stratified by fibrinogen) trial, was an experimental medi-
cine study, designed to test the hypothesis that losmapimod, as an anti-inflammatory agent,
reduces arterial inflammation and concomitantly improves endothelial function (our co-
primary endpoints of the study) in a cohort of COPD patients with evidence of systemic
inflammation, stratified by plasma fibrinogen. Secondary endpoints included safety and tolera-
bility of losmapimod, and the effects of losmapimod on arterial stiffness and blood biomarkers
of inflammation.
Materials and methods
The EVOLUTION study design and protocol have been previously published [14] and the pro-
tocol (S1 Protocol) is included in the Supporting Information. Key trial information is summa-
rised below.
Study design
EVOLUTION was a randomised, double-blind placebo-controlled, parallel-group, stratified
experimental medicine trial, which recruited from two UK tertiary centres (Addenbrooke’s
Hospital, Cambridge and the Royal Brompton Hospital, London). The study was approved by
Cambridge South Research Ethics Committee and was registered with ClinicalTrials.gov
(NCT01541852). It was conducted in accordance with the Declaration of Helsinki and Good
Clinical Practice standards, and written informed consent was obtained from all patients. The
study was active from 1st April 2012 when the first patient was recruited till the 6thAugust 2014
when the final patient recruited completed the study. Based on sample size calculation, the
planned recruitment target of the trial was met.
Participants
Eligible patients were aged 50–85 years, with a known diagnosis of COPD (confirmed by post-
bronchodilator spirometry Forced Expiratory Lung Volume in 1 second/Forced Vital Capac-
ity, (FEV1/FVC ratio <070)), or with spirometry which fulfilled GOLD-Unclassified
(GOLD-U: FEV1/FVC07 and FEV1 <80% predicted) categorisation [15]. However, no
GOLD-U patients were recruited to the study. All patients were current or ex-smokers with at
least a 10-year pack year history and a plasma fibrinogen >28g/L. This level of plasma fibrino-
gen was selected as the stratification threshold for entry to the study because although there is
no evidence of a fibrinogen threshold that stratifies for cardiovascular risk [16], values greater
than 2.7g/L are associated with an increased risk of hospitalisation, and worse FEV1 [17], (and
poor lung function defined by FEV1, is similarly associated with increased cardiovascular risk
[18]). All patients maintained on their standard-of-care medications prior to and during the
study, including prescribed medications for cardiovascular comorbidity and COPD. Full
inclusion and exclusion criteria of the trial including information regarding amendment to the
trial inclusion criteria, are reported in S1 and S2 Tables respectively, and a study flow-chart of
visits and assessments performed are shown in S1 Fig. The trial consort diagram is shown in
p38 mitogen activated protein kinase inhibition and COPD
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Fig 1 with further information also provided in S3 Table. The consort checklist for the EVO-
LUTION trial is found in S1 Appendix.
Randomisation and masking
Subjects were randomised (1:1) to receive either losmapimod 7.5mg or matching placebo
twice daily for 16 weeks. An online coded program was used to randomise patients stratified
by trial site. All trial personnel, including investigators giving trial interventions, assessing out-
comes, and analysis of data, and patients were blinded throughout the study to treatment allo-
cation. Study medication was provided by GSK.
Assessments for primary endpoint
Vascular PET/CT imaging. 18F-Fluorodeoxyglucose PET paired with attenuated cor-
rected computed tomography (FDG PET/CT) imaging of the aorta and carotid arteries was
performed before, and at 16 weeks of treatment, to evaluate tracer uptake as a surrogate mea-
sure of arterial inflammation. Further detailed information regarding imaging is explained in
S1 Methods. For image analysis, Osirix open-source DICOM software v56 (Geneva, Switzer-
land) was used. A region of interest (ROI) including arterial wall and lumen was drawn on
each axial slice of artery on the co-registered PET/CT scan and the maximum Standardised
Uptake Value (SUVmax) recorded. Subsequently, each ROI was normalised by blood FDG
concentration in the superior vena cava or jugular vein (for carotids), to yield an arterial maxi-
mum tissue-to-blood ratio (TBR) as a quantitative measure of arterial tracer uptake (Fig 2).
Slices with a TBR>16, deemed ‘active slices’ were included in analyses.
The arteries were analysed as six arterial territories: the ascending, descending, abdominal
aorta and right and left carotid arteries, and the aortic arch. For each arterial territory and each
scan, the average TBR was calculated by taking the mean of the TBR across all of the slices in
the territory with a TBR>1.6. This produced the TBR of each arterial territory, for each scan.
Change in TBR was pre-defined as the change in average TBR, from post- to pre-dose scans.
The “index vessel” (defined as the arterial territory with the highest average TBR at baseline)
was selected as the a priori focus of interest to determine change over time with treatment or
placebo. Arterial territories that could be the index vessel included the ascending, descending,
abdominal aorta or either carotid artery, but not the aortic arch because higher inter-observer
variability in analysing this region was previously reported. [19] Additionally, we report the
change in TBR in each arterial region individually, including the aortic arch. All scans were
analysed by an experienced reader, anonymised to patient identifiable information, treatment
group, and visit number.
Endothelial function. Endothelial function was assessed by brachial artery FMD pre- and
post-treatment using established ultrasonography techniques [20]. FMD was defined as the
maximum percentage increase in artery diameter, after release of a blood pressure cuff inflated
to supra-systolic pressure for 5 minutes to induce ischemia distal to the site of measurement
(reactive hyperemia). After a 10-minute break, endothelial-independent dilatation was then
assessed. This is the maximum percentage increase in artery diameter after administration of
25 μg of sublingual glyceryl trinitrate (GTN).
Assessments for secondary endpoints
Arterial stiffness. Assessments were performed pre- and post-treatment. After a 15-min-
ute rest, seated brachial blood pressure was recorded (OMRON-750CP, Omron Corp, Japan).
Radial artery waveforms were then obtained using a high-fidelity micromanometer (SPC-301,
Millar Instruments, Texas, USA) and recorded using Sphygmocor software (AtCor Medical,
p38 mitogen activated protein kinase inhibition and COPD
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Fig 1. Consort diagram of EVOLUTION trial. (expanded in S3 Table).
https://doi.org/10.1371/journal.pone.0194197.g001
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Sydney, Australia), which generated a corresponding central waveform and aortic augmenta-
tion index using the software’s validated transfer function. Augmentation index is a composite
measure of arterial wave reflections. Supine carotid-femoral aortic pulse wave velocity
(aPWV), which is a measure of aortic stiffness, was also measured using the same device, as
previously described [21].
Systemic inflammation. Blood samples were collected at days 0, 14, 28, 56, 84 and 112
(16 weeks) of treatment and 2-weeks following cessation of treatment, for measurement of
plasma fibrinogen (Klauss method) [22], and high-sensitivity C reactive protein (hsCRP) using
a clinically validated laboratory assay.
Fig 2. Calculation of arterial tissue-to-blood ratio (TBR) as a measure of arterial inflammation. Calculation of
TBR: ratio of FDG tracer concentration in the artery divided by FDG concentration in the venous blood pool (superior
vena cava for aorta, internal jugular for carotid).
https://doi.org/10.1371/journal.pone.0194197.g002
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Safety. Adverse events, safety laboratory parameters and haemodynamic variables were
assessed throughout the study and electrocardiograms (ECGs) were performed pre- and at 16
weeks of treatment.
Statistical analysis
This was an exploratory trial utilising a sample size calculation similar to our prior PET imaging
trial of losmapimod in atherosclerotic patients on stable statin therapy [5]. We estimated that
30 COPD patients per treatment arm would provide a 90% chance of detecting a difference of
15% change from baseline TBR when comparing losmapimod to placebo. To estimate the treat-
ment effect with 95% confidence intervals (CI) of losmapimod compared to placebo, change
from baseline TBR (or percentage change from baseline FMD, for our co-primary endpoint of
endothelial function) was analysed using linear regression models, with the change from base-
line as the dependent variable, treatment as the independent variable, and baseline value and
treatment site as covariates. Individual regression models were used for the primary endpoints
of index vessel TBR, each arterial territory TBR, and FMD (and GTN), and since change from
baseline value was the dependent variable, only patients with both baseline and follow up data
were included in analysis. For FMD and GTN analyses, pre-test mean brachial artery diameter
was also included as a covariate in each regression model. Similarly, secondary endpoints were
examined using the same regression analysis technique to assess treatment effect of losmapimod
versus placebo. Statistical analysis was performed per protocol, and excluded patients who
required systemic corticosteroids within four weeks of post-dose assessments. The reason for
excluding these patients from primary endpoint analysis was concern that recent treatment
with systemic corticosteroids would confound analysis of the treatment effects of losmapimod.
Safety analysis included all randomised patients who had received at least one dose of study
drug (losmapimod or placebo). Blood biomarker data were log transformed prior to analysis.
Post hoc analysis was performed that excluded subjects who had a COPD exacerbation at any-
time during the trial, where an exacerbation was defined as clinical deterioration in respiratory
symptoms requiring treatment with antibiotics and/or systemic steroids. A post hoc analysis,
which excluded patients with any known cardiovascular medical history at baseline (for exam-
ple hypercholesterolemia, and therefore any patients on statins, or other cardiovascular medica-
tions), was performed. A p-value<005 was deemed significant for all statistical analyses. All
data are presented as mean±standard deviation (SD), percentages, or with 95% confidence
intervals (CI). Analyses were performed using R version 300 for Microsoft Windows with
R-Studio version 098953. Raw data of the trial are provided in S2 Appendix.
Results
The flow of participants in the trial is shown in the consort diagram (Fig 1) and further infor-
mation is provided in the Supporting Information supplement (S3 Table). 160 participants
were assessed for eligibility at enrolment, of whom 73 were randomised to receive either los-
mapimod (n = 36) or placebo (n = 37). Demographics and baseline characteristics of patients
are summarised in Table 1. The mean age of the whole trial cohort was 68±7years, 70% were
male, 14% were current smokers, total pack years smoked were 47±25 years, FEV1 was
135±058 litres (50±21% predicted). Mean fibrinogen pre-dose was 352±063 g/L and hsCRP
was 5.64±739 mg/L.
Primary endpoints
Losmapimod did not significantly reduce the primary imaging endpoint of change in TBR
in the index vessel compared to placebo, (treatment effect of losmapimod on TBR: -005,
p38 mitogen activated protein kinase inhibition and COPD
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(95% CI: -017, 007), p = 042; Fig 3). Table 2 summarises the average TBR of each anatomical
arterial region pre- and post-dose, with point estimates of the treatment effect of losmapimod
adjusted for placebo and site. S4 Table shows treatment effect data with coefficients of covari-
ates from regression analyses also included. The aortic arch was the only anatomical region
where there was a significant treatment effect of losmapimod on TBR compared to placebo.





Age (years) 67±8 68±7
Male 25 (69%) 26 (70%)
Ex-smoker 32 (88%) 34 (91%)
Total pack years (n) 48±24 43±25
BMI (kg/m2) 26±4 26±4
Cardiovascular medical history
CVD disease 5 (14%) 3 (8%)
Hypertension 11 (31%) 7 (19%)
Hypercholesterolaemia 3 (8%) 4 (11%)
Spirometry
FEV1 (L) 132±060 140±054
FEV1 percentage predicted (%) 50±19 52±22
FVC 293±090 312±080
FVC percentage predicted (%) 86±16 88±20
Concomitant inhaled respiratory medication †
ICS and LABA (%) 27 (75%) 29 (80%)
ICS 2 (6%) 2 (6%)
LABA 2 (6%) 4 (11%)
LAMA 23 (63%) 27 (71%)
Haemodynamic assessment
Systolic blood pressure (mmHg) 133±15 138±20
Diastolic blood pressure (mmHg) 77±10 80±10
Heart rate (bpm) 74±12 74±12
Augmentation Index (%) 28±9 25±10
Aortic pulse wave velocity (%) 947±313 1054±248
Systemic Inflammation
hsCRP (mg/l) 36 (21–49) 23 (12–75)
Fibrinogen (g/l) 35 (31, 39) 33 (31–37)
White cell count (x109/L) 71 (57–83) 70 (57–81)
Concomitant cardiovascular medication
Statins (%) 12 (33%) 7 (19%)
Beta-blockers (%) 4 (11%) 0 (0%)
Calcium-channel blockers (%) 8 (22%) 6 (16%)
ACE inhibitors/A2RB (%) 9 (25%) 7 (19%)
Anti-platelets (%) 8 (22%) 4 (11%)
Mean±SD, median (IQR), n (%) are presented.
CVD: history of angina, myocardial infarction, acute coronary syndrome, stroke, or revascularisation procedure. FEV1: Forced Expiratory Lung Volume in 1 second.
FVC: Forced vital capacity. hsCRP: High sensitivity C-reactive protein.
†ICS and LABA: Combined inhaled corticosteroid and long acting beta agonist, ICS: inhaled corticosteroid, LABA: Long acting beta agonist, LAMA: Long acting
muscarinic antagonist. ACE: Angiotensin, A2RB: Angiotensin 2 receptor blockers.
https://doi.org/10.1371/journal.pone.0194197.t001
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Fig 3. Tissue-to-blood ratio (TBR) at baseline and 16 weeks treatment with losmapimod or placebo in the index vessel. Losmapimod had no
significant treatment effect, overall significance p = 042. Lined bars = baseline, solid bars at 16 weeks. Bars = mean values, error bars = 95% CI.
https://doi.org/10.1371/journal.pone.0194197.g003
Table 2. Tissue-to-blood ratio (TBR) for each arterial region at baseline and following treatment with losmapimod or placebo.
Vessel Losmapimod Placebo Treatment Effect of Losmapimod p-value of treatment effect
Baseline 16 weeks Baseline 16 weeks Point Estimate (95% CI)
Mean±SD TBR Mean±SD TBR
Index 212±029 196±029 199±021 193±023 -005
(-017, 007)
042
Arch 210±028 195±023 192±020 193±019 -012
(-022, -003)
001
Ascending 196±026 190±026 185±018 186±020 -004
(-015, 006)
043
Descending 201±031 195±024 192±019 193±020 -004
(-014, 007)
049
Abdominal 199±022 192±024 188±020 190±020 -006
(-016, 003)
020
R Carotid 186±015 181±015 180±019 181±019 -005
(-013, 004)
029
L Carotid 186±020 1.80±019 180±016 188±027 -007
(-019, 007)
033
R Carotid = right carotid, L Carotid = left carotid. Mean±SD are presented. Baseline TBR and treatment site are covariates in linear regression models used to calculate
the treatment effect of losmapimod versus placebo, on each artery listed.
https://doi.org/10.1371/journal.pone.0194197.t002
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For the co-primary endpoint of FMD, there was no significant treatment effect of losmapi-
mod over placebo. The treatment effect of losmapimod did not change FMD significantly
(+04%; 95% CI: -166, 247, p = 070). However, the effect of GTN was marginally higher
(+325%; 95% CI: 041, 61, p = 003) in the losmapimod group compared to placebo, (Table 3
and Fig 4). Of note, there were no significant differences in either primary endpoint when
stratified for study site. S4 Table shows treatment effect data with coefficients of covariates
from regression analyses also included.
Secondary endpoints
For the secondary endpoint of arterial stiffness, there were no statistically significant differences
in augmentation index or aPWV following treatment in the losmapimod or placebo groups.
The treatment effects of losmapimod were also non-significant for augmentation index
(+083%; 95% CI: -4, 6%, p = 073), and aPWV (-001m/s; 95% CI: -095, 093 m/s, p = 098).
We observed a significant decrease in mean fibrinogen in the losmapimod group (10%
reduction compared to 0.3% in placebo group) on Day 14 of treatment (treatment effect -008;
95% CI: -015, -001, p = 003 corrected for baseline and placebo). However, there were no dif-
ferences in fibrinogen levels from 4 weeks of treatment onwards, although there was a trend
Table 3. Percentage change in brachial artery diameter with flow-mediated dilatation (FMD), and dilatation after glyceryl trinitrate (GTN) administration in the
losmapimod and placebo groups of the study.
Losmapimod Placebo Treatment effect of Losmapimod p-value of treatment effect
Baseline 16 weeks Baseline 16 weeks Point Estimate (95% CI)
FMD % 480±256 580±348 417±275 506±404 040
(-166, 247)
070
GTN % 1112±460 1446±704 905±328 977±476 325
(041, 61)
003
Mean±SD are presented. Linear regression models with covariates of baseline percentage change, treatment sites and pre-test mean brachial artery diameter, were used
to calculate treatment effect of losmapimod on FMD and GTN.
https://doi.org/10.1371/journal.pone.0194197.t003
Fig 4. A) Percentage change in brachial artery diameter due to flow-mediated dilatation (FMD). B) Percentage change in brachial artery diameter
following GTN administration, at baseline and 16 weeks treatment with losmapimod or placebo. Losmapimod had no significant effect on FMD
compared to placebo, p = 070, although there was significant change (p = 003) following GTN administration. Lined bars = baseline, solid bars at 16
weeks. Bars = mean values, error bars = 95% CI.
https://doi.org/10.1371/journal.pone.0194197.g004
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throughout the treatment period of the study, of greater attenuation in inflammatory biomark-
ers in the losmapimod group. A rebound of fibrinogen (albeit not hsCRP) above baseline, was
observed two weeks after stopping losmapimod treatment. Fig 5 summarises the trajectory of
fibrinogen and hsCRP values throughout the study.
Losmapimod was well tolerated in this COPD cohort. The frequency of adverse events
reported was similar in the losmapimod and placebo groups (19 versus 12 due to COPD exac-
erbations, respectively, see S5 Table in the Supporting Information supplement). There were
no clinically meaningful or statistically significant changes in laboratory parameters, vital
signs, or ECGs over the course of the study in either treatment group. Serious adverse events
(SAEs) were more frequent in the losmapimod treatment arm, and COPD exacerbations and
pneumonia were the most common SAE reported (S4 Table).
Post hoc analysis
Due to the high number of COPD exacerbations reported in this biomarker-enriched trial, a
pre-specified post hoc analysis was performed to examine only stable patients (excluding
patients who had a COPD exacerbation anytime during the trial). This showed a significant
treatment effect of losmapimod compared to placebo on index vessel TBR (-013; 95% CI:
-025, -002, p = 002). However, there was still no significant treatment effect on FMD
(-022%; 95% CI: -236, 192, p = 083). Furthermore, post hoc analysis excluding patients with
known cardiovascular history (and on cardiovascular medication), showed no significant
treatment effect of losmapimod versus placebo, on index vessel TBR (+010; 95% CI: -015,
013, p = 091), or FMD (+0.55%; 95% CI: -2.71, 3.81, p = 0.73).
Discussion
The primary finding of this experimental medicine study was that the anti-inflammatory p38
MAPK inhibitor, losmapimod, did not attenuate arterial inflammation nor improve endothe-
lial function in systemically inflamed COPD patients, defined by a baseline fibrinogen >28g/l.
To our knowledge, this is the first time fibrinogen has been used as a stratification biomarker
for entry into a drug trial, and arterial inflammation used as a primary endpoint in an inter-
ventional COPD clinical trial.
Although our primary endpoint was negative, overall there was a trend for greater reduc-
tion in arterial inflammation with losmapimod treatment compared to placebo in all vessel ter-
ritories, although this only reached significance in the aortic arch, and a larger study size may
have highlighted treatment differences compared to placebo more clearly. Interestingly, in post
hoc analysis of stable COPD patients who did not exacerbate during the trial, a significant
treatment effect of losmapimod on the index vessel was observed. The respective 7% and 16%
reduction in TBR observed in the aortic arch in the whole cohort, and index vessel in post hoc
analysis when COPD exacerbators were excluded, may have clinical implications. For example
intervention studies report a 6–15% reduction in TBR with other anti-inflammatory treat-
ments such as anti-tumour necrosis-α therapy in rheumatoid arthritis patients, or high-dose
statins in atherosclerosis [23] [24].
This COPD cohort had higher levels of systemic inflammation and index vessel TBR, than
we previously reported in stable atherosclerotic patients [5]. However, the lack of significant
treatment effect of losmapimod on vascular inflammation in this inflamed COPD cohort, is in
contrast to our atherosclerosis data. We previously reported a treatment effect of -010 (95%
CI: 019, -002; p = 001) on TBR after 12 weeks of losmapimod treatment in atherosclerosis
patients already established on stable statin therapy [5]. Important differences between the two
trials include the disease population targeted, and duration of therapy (16 weeks in our current
p38 mitogen activated protein kinase inhibition and COPD
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Fig 5. A) Plot of fibrinogen in the losmapimod and placebo treatment groups. Geometric mean of ratio to baseline
value (95% CI) represented. off drug B) Plot of hsCRP in losmapimod and control groups. Geometric mean of ratio to
baseline value (95% CI) represented. off drug.
https://doi.org/10.1371/journal.pone.0194197.g005
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trial versus 12 weeks previously). However, given the significant post hoc results when COPD
exacerbators were excluded, a possible explanation for lack of significant treatment effect is
that the small treatment effect of losmapimod could have been masked by a much greater effect
of exacerbations on vascular inflammation in COPD, particularly given this was a fibrinogen-
enriched cohort, a group predicated to frequent COPD exacerbations [13]. These data there-
fore suggest that exacerbations are likely to increase arterial inflammation, and provides a
mechanistic explanation for the increased risk of cardiovascular events in COPD patients pre-
senting with exacerbations [25]. We did not examine correlations between systemic inflamma-
tory biomarkers and TBR in this COPD study, since only patients with higher levels of
fibrinogen were included. However, given these COPD patients with systemic inflammation
do have higher levels of arterial inflammation, than what we observed in stable atherosclerosis
patients, supports the concept that arterial inflammation is a plausible mechanism accounting
for increased cardiovascular risk observed in chronic inflammatory conditions [23].
There was no effect of losmapimod on the co-primary endpoint of endothelial function.
However, significantly greater vasodilatation following GTN administration was observed in
the losmapimod group. These data suggest that losmapimod may improve endothelium-inde-
pendent vasodilatation in COPD, and interestingly this effect of losmapimod has been
observed previously in hypercholesterolemic patients [6]. In the hypercholesterolemia study,
however, losmapimod improved endothelium-dependent and endothelium-independent
vasodilatation, but endothelial function was assessed by forearm venous occlusion plethys-
mography and intra-arterial acetylcholine infusion, and the study period was considerably
shorter at 28 days.
Treatment with losmapimod did not alter arterial stiffness in this study. However, this may
be expected since arterial stiffness may not be related to systemic inflammation in COPD
patients, at least in cross-sectional analyses [26]. Mechanical changes to the arterial wall, partic-
ularly of the large central arteries, such as calcification [27], and, or reduced elastin in the arte-
rial wall, potentially due to the detrimental systemic effects of smoking per-se may be a more
robust explanation accounting for the increased arterial stiffness reported in COPD patients.
Pharmacological inhibition of the p38 MAPK pathway is associated with dampening of cir-
culating systemic inflammatory biomarkers particularly in the short-term, and fibrinogen has
most widely been assessed in COPD, and hsCRP in cardiovascular disease. The greatest reduc-
tion in these biomarkers is generally observed in the first 2–4 weeks following MAPK inhibi-
tion, with a gradual drift up from this nadir thereafter, and often a rebound of higher levels
than baseline upon cessation of treatment [3] [5]. The pattern of attenuation in our fibrinogen
data is similar, with a statistically significant reduction in fibrinogen at 2–4 weeks only. In con-
trast, two previous studies of losmapimod in COPD, demonstrated sustained lowering of
fibrinogen with losmapimod treatment, at 12 weeks [4] [28]. The trajectory of fluctuations in
hsCRP across the treatment period in our small trial, which are likely due to exacerbations,
highlight the difficultly of interpreting inflammatory biomarker data in this current study.
Limitations of this exploratory study are the relatively small study size which may have
restricted our ability to detect a smaller treatment effect than we predicted, based on data from
a different population [5]. Further, the exacerbations which occurred in this cohort, which is
consistent with the current understanding that fibrinogen predicts these events, makes dis-
criminating small anti-inflammatory effects more difficult. Moreover, we chose a 4 month
treatment period, whereas losmapimod reduced arterial inflammation in atherosclerosis
patients at 3 months [5], and improved endothelial function in hypercholesterolemic subjects
following 1 month of treatment [6]. These data suggest that the ideal treatment duration of los-
mapimod may be in the acute setting, or for shorter periods of therapy, similar to the use of
corticosteroids in exacerbations.
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To the best of our knowledge, this is the first trial to use fibrinogen as a stratification bio-
marker for entry to a COPD study. The clinical implications of fibrinogen reduction previ-
ously reported in losmapimod studies in COPD are currently unclear, but fibrinogen in
COPD, is associated with poor outcomes and is a more stable biomarker than CRP [29], which
supported its use as a stratification biomarker in this study. Indeed, the FDA has qualified
fibrinogen as a drug development tool to be used in studies where patients are at high risk of
exacerbations and mortality [13], and the stable levels of fibrinogen in the EVOLUTION pla-
cebo group over 4 months, and incidence of COPD exacerbations in the study, further support
its utility as a drug development tool.
In summary, 16 weeks treatment with losmapimod was well tolerated but demonstrated no
effect on index vessel inflammation and only a short-term reduction in systemic inflammation
biomarkers in this cohort of COPD patients with evidence of systemic inflammation. Although
endothelial-independent vasodilatation responses improved with losmapimod, there was no
change in endothelial-dependent vasodilatation. These findings suggest that losmapimod is
unlikely to be an effective long-term treatment for the adverse cardiovascular extra-pulmonary
manifestations of COPD.
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